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INTRODUCTION
VAEs consist of two components, the encoder and decoder. The encoder is a function that takes in a visual field and compresses it to a lower-dimensional space. The decoder (sometimes called the generator) is a probabilistic distribution that maps the latent features back to the original high-dimensional image space. Since the decoder is trained to reconstruct the original data using a small number of latent dimensions, those features end up representing key aspects of the data. In other words, the encoder-decoder process is forced to learn the most important features of the original data. Furthermore, because there is a regularization prior, the VAE learns features that are homogenous, and therefore can be interpreted clinically. The bottleneck structure of the VAE is presented in Figure 1A .
Both the encoder and decoder used neural networks with deep learning. The encoder is itself a network, but for the decoder, the network is the mean of a Gaussian distribution. Details of both networks can be found in Figure 1B . The encoder of the VAE is comprised of two 2D convolutional layers, a reshaping layer and a fully-connected dense layer. The decoder begins with a fully-connected dense layer, followed by a reshaping layer, and then a sequence of deconvolutions, which up-sample until the original 12 x 12 dimension is reached. All layers use a 3 x 3 kernel size and a stride of two, and the activation is a rectified non-linear unit transformation, except for F1 and D3, which used the identity and sigmoid activations, respectively.
For each choice of latent dimension, the model was trained using the Adam optimizer, an extension of stochastic gradient descent, using 50 epochs and a batch size of 100 24 ; we used a learning rate of 1e-4. The training epoch with the minimal validation loss was chosen as optimal. The VAE was implemented using the deep learning library Keras (version 2.2) 25 with Tensorflow (version 1.9) 26 backend, all within RStudio (3.5.1) 27 .
Dimension of the Latent Features
The dimension of the latent space is a parameter that was specified to reflect the number of latent features that can adequately explain the high-dimensional visual fields. In this study, we explored the performance of the VAE over latent dimensions ranging from one to ten. Throughout the analysis all results based on the VAE are reported for all ten variations of the latent dimension in an attempt to determine the preferred latent space.
Rates of Visual Field Progression
We used the latent features of the VAE to determine rates of progression for glaucoma patients in the test dataset. For each patient, we obtained the latent features corresponding to each visual field using the encoder. Then, we studied the longitudinal trends of the latent features (instead of the complex 52-dimensional visual field). In particular, we quantified progression based on the global rate of change across all features from a model. In order to calculate this global rate, we performed ordinary least squares (OLS) regression with a zero-sum constraint on the design matrix; thus, allowing us to perform a hypothesis test on the mean rate of change across time. Progression was defined as a significant global rate of change based on a two-sided hypothesis test with type-1 error of 0.05.
This rate of visual field progression can be interpreted as the speed of deterioration for a patient's visual field features, where features represent some lower dimensional representation of the visual field. This is reminiscent of SAP MD, which is a comparison of a current visual field to an age adjusted healthy baseline in one-dimension. As such, for comparison we used standard rates of visual field progression of MD using OLS linear regression across time, with progression defined as a significantly negative rate of change over time (alpha = 0.05).
Finally, in the absence of a gold standard of progression, we compared the progression methods by matching their specificities at 95%. Because both methods are p-values with a type-1 error of 0.05, this is automatically achieved with a cutoff of 0.05. Therefore, the method with the higher rate of detecting progression in the glaucoma patients in the test dataset has superior operating characteristics. Note that this is not a sensitivity, because not all patients are progressing, but rather a progression hit rate. For each method, we estimated hit rate percentage at two, four and six years from baseline visits and also for all patient follow-up. Only visits that occurred on or before the cutoff time are included in the analysis. This imitated a clinical setting where each metric is calculated at every visit and progression is diagnosed. For hypothesis testing, bootstrapped confidence intervals were presented 28 .
Predicting Future Visual Fields
An advantage to the VAE modeling framework is the ability to generate visual fields from its latent features through the decoder. This motivated a method for predicting future visual fields through a two-stage procedure. First, for a longitudinal collection of visual fields, we obtained their corresponding latent features (obtained from the encoder) and modeled each dimension independently using OLS linear regression. Then, we used the predicted values of the latent features to generate future visual fields using the decoder. Note that because the decoder is a mean process, the generated visual fields are de-noised.
We assessed the prediction accuracy of this two-stage approach by predicting the fourth, sixth, and eighth follow-up visits from the first three visits of all patients in the test dataset. We also looked at prediction accuracy in glaucoma patients only. Prediction accuracy was assessed using mean absolute error (MAE) for only the 52 informative locations (i.e., not the full 12 x 12 image). All results are compared to the established technique of visual field prediction, PW linear regression. One-sided Wilcoxon signed rank tests are presented to formally compare if the MAE from the VAE is smaller than from PW, using a Bonferroni corrected type-1 error, 0.05/60 0.0008.
RESULTS
This study included 29,701 visual fields; however, 540 visual fields were excluded due to falsepositives greater than 15% or fixation error greater than 33%. This yielded 29,161 usable visual fields from 3,832 eyes. These patient eyes had an average follow-up of 4.95 years with a mean of 7.61 visits. Mean age at baseline was 60.94, mean baseline MD was -3.55 dB and mean baseline PSD was 3.42. From the usable visual fields, we created training, validation, and test datasets, by randomly sampling eyes with probability 80%, 10%, and 10%, respectively. Population characteristics for each dataset are presented in Table 1 . The models were trained for 50 epochs and the optimal losses are presented in Figure 2 for the training and validation datasets across models with varying latent dimensions. From the figure it is clear that the reconstruction losses were nearly zero for all models and that the regularization loss decreased with the number of dimensions after three dimensions.
We investigated the rates of visual progression determined from the latent space of the VAE and SAP MD. To motivate using the VAE for detecting progression, we have presented the longitudinal follow-up for examples patients of each disease status in a two-dimensional latent space ( Figure 3A) . The predicted trajectories are presented as arrows and the observed longitudinal follow-up are underlaid using muted colors. Furthermore, the location of a healthy visual field (blue square) is displayed, where healthy is defined as the mean visual field of all the healthy eyes. In Figure 3B -C, the first and second latent feature are shown across time with OLS regression lines indicating rates of change for each feature. Our defined VAE progression metric is the average of feature slopes, which is a calculation of the speed of movement through the latent space.
In Figure 4 , the progression detection hit rates are presented for of each of the diagnostic measures. The vertical line in each frame is a representation of the 95 th percentile of MD, and thus metrics with no overlap are significantly superior. At two years from baseline, the VAE models with five, seven, and eight dimensions were significantly superior at detecting progression; while at four years the VAE models with seven and eight dimensions remained significant. The significance disappears by six years, however the VAE models with seven and eight dimensions remain superior.
To verify that the trained models effectively learned the generative process we assessed the predictive capacity and the results are presented in Figures 5 and 6 , plus Table 2 . Figure 5 shows boxplots of the MAE for all patients in the test dataset along with glaucoma patients only. The MAE were most similar between VAE and PW when predicting the fourth visit; however, the VAE is generally superior with only the model with one dimension not significantly superior (P = 0.1528), with the rest having P-values less than 0.0001. A similar pattern holds for glaucoma patients, however, now only the VAE models with more than three latent dimensions were significantly superior to PW. Superiority of the VAE prediction increased when predicting further into the future, to visits six and eight, as all VAE models had significantly superior prediction, for all patients and those with glaucoma ( Table 2 ).
The ability of the VAE to predict future visual fields is further illustrated in Figure 6 , where predictions are presented of an example glaucoma patient with severe disease. The predictions from the VAE model are stable when predicting future patterns of vision loss, while PW deteriorates, with a MAE of 36.43 when predicting the eighth visit. In Figure 6B , the predicted visual field at the eighth visit is presented using the Zeiss printout, for the true visual field, PW and the VAE model with eight dimensions.
To further demonstrate the clinical utility of the VAE, we visualized it with a twodimensional latent space across clinical measures. Figure 7 shows the relationship between the VAE latent feature space and clinical variables, disease status, age, MD, and PSD. Finally, in Figure 8 , we presented the generative distribution derived from the VAE for two latent dimensions, with the predicted trajectories of each of the example patients included. Overlaying each path is a blue line that indicates the distance traveled in the first year of follow-up, which is constant across time.
DISCUSSION
In this manuscript, we developed and validated a novel deep learning algorithm that produced a unified framework for learning the generative process of visual fields and detecting rates of glaucoma progression. The VAE used a low-dimensional latent space representation of the more complex and high-dimensional visual field image to produce a clinically relevant latent space. This was achieved through the model structure of the VAE, which learned the latent features through both a compression (i.e., encoder) and generative (i.e., decoder) process. Standard techniques for learning latent features, such as probabilistic principle components, factor analysis or independent components analysis, only include the compression component and, consequently, the latent space can often be less realistic 7, 29 . Furthermore, these standard techniques assume the latent features are a linear combination of the original image, while the VAE uses deep learning to allow for arbitrarily non-linear mappings.
Previous studies have used machine learning approaches to assess glaucomatous damage from visual fields 13, 14, 30, 31 . In these studies, the glaucomatous status of the eyes was determined either by clinical measures or by clinical expertise, making the machine learning performance dependent on the chosen gold standard. This type of technique can be limited, because the endpoint of interest is often inaccurate or different from the true clinical end-point. We circumvented this issue in our study by using an unsupervised method. Instead of training against a noisy gold standard, the VAE trains a visual field against itself, in the process developing a generative model through clinically interesting latent features.
To visualize the latent features for visual fields, we presented the latent space in twodimensions for clinical measures, glaucoma status, age, MD, and PSD ( Figure 7 ). Through inspection of these figures the latent space comes to life. Across all clinical measures it is clear that patients with no evidence of glaucoma reside near the origin, as this is the location of the normal disease patients, and young patients with MD and PSD values near zero. As the latent features increase in either dimension the disease severity increases. In particular, both age and MD values appear to become more severe (i.e., older age and more negative MD) with an increase in either of the features or a combination of both. In contrast, PSD only demonstrates more severity (i.e., larger values) with an increase in either of the latent features, but not both. This illuminates a clinical phenomenon, that MD and age are linear risk factors, while PSD identifies local defects, which are typically not evident in the late stages of disease.
The latent space can also be used to visualize the generative process for visual fields. In Figure 8 , the distribution of visual fields across the two-dimensional latent space was displayed. This presentation provides more clinical context to the latent space, as the generative process is a smooth representation of the variability in visual fields. In particular, we can see the patterns of disease severity, as an increase in the second latent feature appears to indicate a global worsening in the functional vision, while the first feature dictates worsening patterns in the superior (or inferior) hemisphere when moving to the right (or left) of the origin. Because the VAE produced a latent feature space that was clinically informative, it had utility for determining rates of progression.
In particular, we leveraged the clinical interpretation of the latent space to calculate progression rates by measuring the rate of a patient's movement through the generative distribution. We formally defined the progression rate based on the average of the rates across features. This process was exemplified through the visual fields of a normal, suspect, and glaucoma patient in Figure 3 . The movement of each of the patients through latent space was displayed, along with the trajectories of the features across time. The glaucoma patient has the highest rate, indicated by the large positive slope in the first feature. In Figure 8 , the trajectory of each of the example patients overlays the generative process, with an indicator of the rate of movement through latent space (blue line). This novel presentation of the trajectories through the distribution of visual fields provided a literal clinical road map for making treatment decisions.
We provided evidence that the rate of change through latent space is superior to MD (Figure 4 ) at two and four years from baseline follow-up for a number of VAE models, in particular with eight dimensions. This is not surprising, as MD can be thought of as a onedimensional latent space representation of a visual field 32 . Therefore, it follows that the performance of the VAE would improve upon MD. Although the VAE models do not significantly outperform MD in the long run, this finding is nonetheless important because detection of change and intervention in the early years of follow-up can reduce a patient's likelihood of vision loss 33 .
Furthermore, the VAE can be used to predict the future location of a patient's latent features ( Figures 5 and 6 , Table 2 ). This allows for accurate predictions of future visual fields, which can help illuminate patterns and severity of progression. Such predictions of whole visual fields are obviously not possible with a single global metric such as MD. Even if one uses PW regression, the VAE was shown to have superior prediction capabilities. The predictions in Figure 6 demonstrated the benefits of using the VAE as compared to PW regression. In particular, while the PW method was highly susceptible to local variability, the VAE produced stable (i.e., smooth) predictions. This resulted in predictions that were robust to the variability of individual entries and consequently, the true disease pattern visible is better illuminated.
The prediction capability of the VAE model, including patients with patterns in their visual fields, is reassuring, as global methods, like MD, typically fail at detecting localized defects 33 . The flexibility of the VAE, to not only improve rates of detecting progression over the global MD method, but also maintain superior predictions over PW regression, makes it clinically useful. In particular, because the VAE has the ability to detect progression at higher rates in the early years from baseline, clinicians will need fewer visits to obtain accurate detection of progression; thus, limiting the burden on patients.
A potential limitation, or motivation for future work, is that when training the deep learning model, we treated each of the visual fields as independent images. We overcame this limitation by modeling a patient's longitudinal visual fields series in latent space, which we showed to be an effective method for assessing rates of progression. In the future, we could make improvements by learning a generative model for longitudinal series of visual fields, instead of a singular image. This would be a powerful technique for clustering patients, not by their visual fields, but by the characteristics of their progression.
Another extension to the method presented in this manuscript is to generate synthetic glaucomatous visual fields to be used as a benchmark dataset to validate new methods for glaucoma research. Existing methods attempt to generate longitudinal visual fields by modelling PW relationships across time with potentially non-linear fits 34, 35 , however they typically ignore spatial correlations in the visual field or can only predict stable fields. The decoder from the VAE can be used to simulate glaucomatous visual field series that accounts for spatial dependencies and the highly-nonlinear PW trends.
In conclusion, this manuscript showed the potential use of the VAE latent space for assessing rates and trajectories of glaucoma progression. The rates of progression can be considered a multi-dimensional extension of MD with improved abilities to detect progression and the additional benefit of a generative technique to predict future patterns and severity of visual fields. Years from baseline visit Latent Dimension: 1 Years from baseline visit Latent Dimension: 2 
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